Pharmacokinetics/pharmacodynamics of phage therapy: a major hurdle to clinical translation
Clinical Microbiology and Infection · 2023-06 · 29 (6) · 702-709
DOI: 10.1016/j.cmi.2023.01.021 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinical Microbiology and Infection, 2023-06. Verfasst von Sue C Nang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Biomedicine Discovery Institute, Infection Program, Department of Microbiology, Monash University, Victoria, Australia. Hauptthemen laut MEDLINE: Phage Therapy, Anti-Infective Agents, Bacteriophages. Die Arbeit wurde bisher 174-mal zitiert (Crossref) und nennt 67 Literaturangaben. Gefördert von: National Health and Medical Research Council, Office of Health and Medical Research, National Institutes of Health.
Abstract (Originalsprache)
BACKGROUND: The increasing emergence of antimicrobial resistance worldwide has led to renewed interest in phage therapy. Unlike antibiotics, the lack of pharmacokinetics/pharmacodynamics (PK/PD) information represents a major challenge for phage therapy. As therapeutic phages are biological entities with the ability to self-replicate in the presence of susceptible bacteria, their PK/PD is far more complicated than that of antibiotics. OBJECTIVES: This narrative review examines the current literature on phage pharmacology and highlights major pharmacological challenges for phage therapy. SOURCES: Included articles were identified by searching PubMed and Google Scholar till June 2022. The search terms were 'bacteriophage', 'antimicrobial', 'pharmacokinetics' and 'pharmacodynamics'. Additional relevant references were obtained from articles retrieved from the primary search. CONTENT: In this review, phage PK is first discussed, focusing on absorption, distribution, metabolism, and elimination. Key factors affecting phage antimicrobial activities are reviewed, including multiplicity of infection, passive and active phage therapy, and the involvement of the human immune system. Importantly, we emphasize the impact of phage self-replication on the PK/PD and the fundamental phage characteristics that are required for PK/PD modelling and clinical translation. IMPLICATIONS: Recent progress in phage pharmacology has shown that we are in a far better position now to treat infections with phage therapy than a century ago. However, phage therapy is still in its infancy when compared to antibiotics due to the scarce pharmacological knowledge (e.g. PK/PD). Optimization of phage PK/PD is key for translation of phage therapy in patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Biomedicine Discovery Institute, Infection Program, Department of Microbiology, Monash University, Victoria, Australia.
- Westmead Hospital, Western Sydney Local Health District, Westmead, New South Wales, Australia; Centre for Infectious Diseases and Microbiology, Westmead Institute for Medical Research, Westmead, New South Wales, Austral…
- Advanced Drug Delivery Group, Sydney Pharmacy School, Faculty of Medicine and Health, The University of Sydney, New South Wales, Australia; AcuraBio Pty Ltd, Darra, Queensland, Australia.
- Division of Pharmacotherapy and Experimental Therapeutics, Eshelman School of Pharmacy, University of North Carolina, North Carolina, USA.
- Advanced Drug Delivery Group, Sydney Pharmacy School, Faculty of Medicine and Health, The University of Sydney, New South Wales, Australia.
- Biomedicine Discovery Institute, Infection Program, Department of Microbiology, Monash University, Victoria, Australia. Electronic address: jian.li@monash.edu.
Förderung
- National Health and Medical Research Council
- Office of Health and Medical Research
- National Institutes of Health
- Monash University
- National Institute of Allergy and Infectious Diseases
Zitieren
APA
Nang, S. C., Lin, Y. W., Petrovic Fabijan, A., Chang, R. Y. K., Rao, G. G., Iredell, J., Chan, H. K., & Li, J. (2023). Pharmacokinetics/pharmacodynamics of phage therapy: a major hurdle to clinical translation. Clinical Microbiology and Infection, 29(6), 702-709. https://doi.org/10.1016/j.cmi.2023.01.021
Vancouver
Nang SC, Lin YW, Petrovic Fabijan A, Chang RYK, Rao GG, Iredell J, et al. Pharmacokinetics/pharmacodynamics of phage therapy: a major hurdle to clinical translation. Clinical Microbiology and Infection. 2023;29(6):702-709. doi:10.1016/j.cmi.2023.01.021
BibTeX
@article{Nang2023,
author = {Nang, Sue C and Lin, Yu-Wei and Petrovic Fabijan, Aleksandra and Chang, Rachel Y K and Rao, Gauri G and Iredell, Jonathan and Chan, Hak-Kim and Li, Jian},
title = {Pharmacokinetics/pharmacodynamics of phage therapy: a major hurdle to clinical translation},
journal = {Clinical Microbiology and Infection},
year = {2023},
volume = {29},
number = {6},
pages = {702--709},
doi = {10.1016/j.cmi.2023.01.021}
}
EUVIMED